Get Connected:

 

Latest News

Trending News Today: Study Links Prenatal Nicotine Exposure to ADHD in Offspring
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
Top news of the day across the health care landscape.
 
Top news of the day across the health care landscape.
 
Top news of the day across the health care landscape.
 
Top news of the day across the health care landscape.
 
Top news of the day across the health care landscape.
 
Following recent drug pricing hearings on Capitol Hill, the Trump Administration proposed a rule targeting the prescription drug rebate system.  
View More >

From the Journals

Specialty Drugs Remain a Costly Concern for Employers With No Easy Answers
Costs remain the top concern of healthcare purchasers of pharmacy benefits, but employers are also concerned with ensuring appropriate use of medication and adherence to medication, according to a new report from the Pharmacy Benefit Management Institute (PBMI).
With discussion and debate happening for months in Washington, DC, over drug pricing and the role of pharmacy benefit managers (PBMs), the Institute
for Clinical and Economic Review (ICER) published a white paper this week that analyzes 3 possible alternatives to the pharmaceutical rebate system fostered by PBMs.
Several efforts are underway nearly a year after the Trump administration released its blueprint to lower drug prices in May 2018, but tracking their outcomes depends on what metric is used to define drug prices, according to a session at the Academy of Managed Care Pharmacy Managed Care & Specialty Pharmacy Annual Meeting, held March 25-28 in San Diego, California.
A day after stakeholders told a House of Representatives subcommittee about problems accessing and paying for insulin, Cigna and its pharmacy benefit manager Express Scripts said they are launching a program for patients with diabetes in their commercial plans so that they pay no more than $25 for a 30-day supply of insulin.
A policy from the Trump administration to benefit patients and alleviate the high cost of prescription drugs would eliminate rebates from pharmaceutical
companies to pharmacy benefit managers.
Prescription benefits consultant Chris Robbins, chief executive of cer of Arxcel, describes the finger-pointing in Congress over lowering drug costs this way: “If it weren’t so true, it might be almost humorous.”
New proposed rules for the Medicare Part D drug program could affect the manner in which pharmacy benefit managers administer the program and could impact profitability.
Upcoming Partner Events